I lead international clinical research at the interface of infectious and chronic diseases, with a focus on post-tuberculosis cardiovascular, pulmonary vascular, and lung complications. As Chief Principal Investigator of the EDCTP-funded StatinTB trial—one of the first to assess anti-inflammatory therapy in post-TB lung disease—I use PET/CT as the primary endpoint and lung and heart MRI as secondary endpoints. I received PET/CT training from the Cliff Barry research group at the NIH. Findings from StatinTB and the PredictTB trial amongst others highlight the urgent need to understand lung destruction and repair during TB treatment. Over the past 15 years, I have secured funding from EDCTP, the United States National Institutes of Health (NIH), the Gates Foundation, and university grants, and have published over 80 peer-reviewed papers in NEJM, The Lancet, and The European Heart Journal. Trained at Charité Hospital, Berlin, I have also worked in corporate drug safety at Bayer HealthCare and with Médecins du Monde. Since 2009, I have been with the Department of Medicine at the University of Cape Town, appointed Associate Professor in 2017, founding the General Medicine & Global Health Research Group and a Cape Town climnical trial site. I co-chair the PASCAR Clinical Research Training Task Force, hold a clinical appointment at the University of Zurich, and serve as Chief Medical Officer at the Hirslanden Medical Center in Zug.